Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Oncology Stories

2014-04-07 08:30:00

Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose...

2014-04-07 08:29:57

PRINCETON, N.J., April 7, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant...

2014-04-07 04:21:10

ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy EMD Serono,...

2014-04-06 12:20:19

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies - including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 - that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 - 9. "Harnessing Breakthroughs - Targeting Cures" is the theme of this year's...

2014-04-04 23:36:36

Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment and no one is more excited than Dr. Mai Brooks. Perjeta (pertuzumab) In September 2013, the FDA approved Perjeta for use in combination with Herceptin (trastuzumab) and docetaxel for the...

2014-04-04 23:31:28

St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project finds TP53 gene is altered in nearly all osteosarcomas; results help explain how tumors withstand radiation therapy. Memphis, Tenn. (PRWEB) April 03, 2014 The St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in...

2014-04-04 23:22:41

Researchers in Italy say their review of studies on the link between selenium and malignancies like bladder cancer turned up too little evidence to support supplementation. Raleigh, NC (PRWEB) April 04, 2014 Italian scientists say patients fighting bladder cancer and other types of cancer are not likely to get any benefit from the metalloid nutritional supplement, selenium. The new meta-analysis has just been posted on the Cancer Monthly website and can be read by clicking here....

2014-04-04 23:01:00

A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being presented this weekend at the American Association for Cancer Research Annual Conference 2014) details the discovery of a new genetic driver of bladder cancer: silencing of the gene AGL. Aurora, CO (PRWEB) April 04, 2014 A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being...

2014-04-04 12:27:12

Initiative aims to help women at high risk and their health care providers TORONTO, April 4, 2014 /CNW/ - Today, on behalf of the Honourable Rona Ambrose, Federal Minister of Health, Stella Ambler, Member of Parliament for Mississauga South, announced a new High Risk Breast Cancer Project, funded by the Public Health Agency of Canada, which aims to increase awareness and understanding among women, health care providers and the general public about the factors that place women at high risk...

2014-04-04 12:23:54

These genes could explain why some women with high-risk mutations suffer from cancer while others do not Today we know that women carrying BCRA1 and BCRA2 gene mutations have a 43% to 88% risk of developing from breast cancer before the age of 70. Taking critical decisions such as opting for preventive surgery when the risk bracket is so wide is not easy. Spanish National Cancer Research Centre (CNIO) researchers are conducting a study that will contribute towards giving every woman far...